Sysmex (6869) · TargetRestated
Achieved an undisputed No. 1 position in the U.S. blood cell count testing market
First written in FY2017. 1 of 2 entries say "Restated". Latest entry: FY2018.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Establishing a leading position in the US blood cell counting testing marketA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2018RestatedAnnual report
「In the hematology testing field, we will continue to grow and strengthen profitability by achieving an absolute No. 1 position in the US, strengthening sales promotion to Grade 2 hospitals and below in China, and achieving high growth in emerging markets.」
It reiterates the goal of achieving an absolute No. 1 position in the US hematology testing market and the initiatives in China and emerging markets. - FY2017First statedAnnual report
「In the hematology testing field, we will continue to grow and strengthen profitability by achieving an absolute No. 1 position in the US, strengthening sales promotion to Grade 2 hospitals and below in China, and achieving high growth in emerging markets.」
It states for the first time the goal of achieving an absolute No. 1 position in the US hematology testing field.